Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K39/215

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2022/203963CORONAVIRUS VACCINE FORMULATIONS
WO 29.09.2022
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/US2022/020974 Applicant NOVAVAX, INC. Inventor SMITH, Gale
Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.
2.WO/2022/200811MODIFIED CHIMERIC CORONAVIRUS SPIKE PROTEIN FOR ENHANCEMENT OF VIRAL TITERS
WO 29.09.2022
Int.Class C07K 14/165
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/GB2022/050759 Applicant IOSBIO LTD Inventor DREW, Jeffrey
The disclosure relates to the production of viral particles, in particular adenoviral particles for use in vaccines. Modified chimeric coronavirus spike antigens are disclosed, together with polynucleotides encoding said antigens, viral particles and methods of production/formulation of the viral particles.
3.WO/2022/203721COMPOSITIONS AND METHODS FOR INHIBITING PROTEOLYTIC ACTIVATION OF VIRUSES
WO 29.09.2022
Int.Class A61K 36/9066
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
36Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
18Magnoliophyta (angiosperms)
88Liliopsida (monocotyledons)
906Zingiberaceae (Ginger family)
9066Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
Appl.No PCT/US2021/054759 Applicant MAJEED, Muhammed Inventor MAJEED, Muhammed
The present invention discloses use of a composition comprising enriched in bisdemethoxycurcumin, specifically a composition comprising not less than 20% w/w bisdemethoxycurcumin, 10-35% w/w demethoxycurcumin and 10-50% curcumin in preventing the activation of viral spike proteins by inhibiting the activity of proteolytic enzymes and in inhibiting the replication and growth of pathogenic viruses, specifically SARS-CoV-2 in mammalian cells. The invention also discloses the potential of the above composition in managing SARS-CoV-2 induced infections.
4.WO/2022/200384NOVEL USE OF AN IMMUNOGENIC OR VACCINAL COMPOSITION AGAINST COVID-19
WO 29.09.2022
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/EP2022/057548 Applicant EYE VACC Inventor SCHRAGE, Norbert
The present invention relates to an anti-SARS-CoV-2 immunogenic or vaccinal composition for use in the treatment of COVID-19, the composition being characterised in that it is administered to the ocular mucosa and/or the urogenital mucosa.
5.WO/2022/200385NOVEL USE OF AN IMMUNOGENIC OR VACCINAL COMPOSITION
WO 29.09.2022
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/EP2022/057549 Applicant EYE VACC Inventor BLOMET, Joël
The present invention relates to an immunogenic or vaccinal composition comprising a marker, for use in the prevention and/or treatment of an infection caused by at least one pathogen, the composition being characterised in that it is administered to the ocular mucosa and/or the urogenital mucosa.
6.20220305112NOVEL METHODS AND USES
US 29.09.2022
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No 17680433 Applicant GLAXOSMITHKLINE BIOLOGICALS SA Inventor Robbert Gerrit VAN DER MOST

The present invention relates to immunisation with a coronavirus spike antigen and a squalene emulsion adjuvant to elicit broad immune responses, and to related aspects.

7.4062930NEW APPLICATION OF AN IMMUNOGENIC OR VACCINE COMPOSITION AGAINST COVID-19
EP 28.09.2022
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No 21180476 Applicant EYE VACC Inventor SCHRAGE NORBERT
La présente invention concerne une composition immunogène ou vaccinale contre le SARS-CoV-2, pour son utilisation dans le traitement de la Covid-19, caractérisée en ce qu'elle est administrée sur la muqueuse oculaire et/ou la muqueuse uro-génitale.
8.2605312Compositions and methods for delivery of RNA
GB 28.09.2022
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No 202208100 Applicant HDT BIO CORP Inventor AMIT KHANDHAR
The disclosure provides nanoemulsion compositions and methods of making and using thereof to deliver a bioactive agent such as a nucleic acid to a subject. The nanoemulsion composition comprises a hydrophobic core based on inorganic nanoparticles in a lipid nanoparticle that allows imaging as well as delivering nucleic acids. Methods of using these particles for treatment and vaccination are also provided.
9.102021005396PRODUÇÃO DE PARTÍCULAS POLIMÉRICAS CONJUGADAS COM ANTÍGENOS DO VÍRUS SARS-COV-2 E DE OUTRO AGENTES INFECCIOSOS PARA ENSAIOS IMUNOLÓGICOS E IMUNIZAÇÃO CONTRA COVID-19 E OUTRAS DOENÇAS
BR 27.09.2022
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No 102021005396 Applicant UNIVERSIDADE FEDERAL DO PARANA Inventor MARCELO MÜLLER DOS SANTOS
PRODUÇÃO DE PARTÍCULAS POLIMÉRICAS CONJUGADAS COM ANTÍGENOS DO VÍRUS SARS-COV-2 E DE OUTRO AGENTES INFECCIOSOS PARA ENSAIOS IMUNOLÓGICOS E IMUNIZAÇÃO CONTRA COVID-19 E OUTRAS DOENÇAS. A invenção descrita consiste no processo de obtenção de partículas poliméricas em micro e nanoescala e de antígenos recombinantes que juntos formam um veículo imunizante. A invenção descreve os seguintes detalhes técnicos: (i) obtenção das nanopartículas do polímero polihidroxibutirato, (ii) expressão, purificação e imobilização do antígeno na superfície das partículas e (iii) imunização de camundongos e análise dos títulos vacinais contra o antígeno. Embora a invenção tenha sido desenhada e demonstrada como imunizante contra SARS-CoV-2, a invenção tem amplo potencial de aplicação na área médica pois é adaptável para imobilizar antígenos de outros agentes infecciosos.
10.20220296700SYNTHETIC PLASMID DNA VACCINE EXPRESSING A CODON-OPTIMIZED SARS-COV-2 SPIKE PROTEIN AND METHODS FOR ITS USE
US 22.09.2022
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No 17203116 Applicant KING ABDULAZIZ UNIVERISTY Inventor Anwar M. Hashem

A synthetic DNA vaccine against SARS-CoV-2 infection comprises a codon-optimized coding sequence for optimal mammalian expression of a pSARS2 spike glycoprotein (pSARS2-S). The signal peptide may be replaced with the signal peptide from the human IgG2 heavy chain. Systemic S1-specific IgG antibodies and neutralizing antibodies (nAbs) were significantly induced in mice at 2 weeks-post three injections with 100 μg of the pSARS2-S vaccine via intramuscular (IM) needle injection. IM immunization induced Th1-skewed and long-lasting IgG response in BALB/c mice. Immunogenicity and induction of nAbs were enhanced with a needle-free delivery system, wherein two doses were sufficient to elicit significant levels of systemic S1-specific IgG antibodies and nAbs via IM or intradermal immunization.